Abstract
During the last few years, adoptive cellular therapy (ACT) — the isolation of antigen-specific lymphocytes, their ex vivo expansion and activation, and subsequent autologous administration — has been tested for treatment of melanoma tumours. Initial ACT used melanoma -infiltrating lymphocytes (TIL) that often contain tumour reactive lymphocytes, of diverse, mostly unknown, specificities [1, 2]. Recently, the identification of melanoma antigens [3] and the development of techniques for selection and expansion of epitope specific T cells has opened the way to the use of tumour antigen specific T cells, and importantly to immune follow up of ACT [4-9]. Despite these advances, several issues remain to address to achieve the major aims of ACT, as the rapid production of clinical grade T cells capable of eliciting a significant destruction of tumour tissue.
Keywords: lymphocyte, TCR transgenic T cells, melanoma infiltrating lymphocytes, tumour antigen, Peripheral Blood Mononuclear Cell
Current Cancer Therapy Reviews
Title: Lymphocyte Biomarkers of Clinical Responses to Adoptive Immunotherapy of Malignant Melanoma
Volume: 4 Issue: 2
Author(s): Nathalie Labarriere, Brigitte Dreno and Francine Jotereau
Affiliation:
Keywords: lymphocyte, TCR transgenic T cells, melanoma infiltrating lymphocytes, tumour antigen, Peripheral Blood Mononuclear Cell
Abstract: During the last few years, adoptive cellular therapy (ACT) — the isolation of antigen-specific lymphocytes, their ex vivo expansion and activation, and subsequent autologous administration — has been tested for treatment of melanoma tumours. Initial ACT used melanoma -infiltrating lymphocytes (TIL) that often contain tumour reactive lymphocytes, of diverse, mostly unknown, specificities [1, 2]. Recently, the identification of melanoma antigens [3] and the development of techniques for selection and expansion of epitope specific T cells has opened the way to the use of tumour antigen specific T cells, and importantly to immune follow up of ACT [4-9]. Despite these advances, several issues remain to address to achieve the major aims of ACT, as the rapid production of clinical grade T cells capable of eliciting a significant destruction of tumour tissue.
Export Options
About this article
Cite this article as:
Labarriere Nathalie, Dreno Brigitte and Jotereau Francine, Lymphocyte Biomarkers of Clinical Responses to Adoptive Immunotherapy of Malignant Melanoma, Current Cancer Therapy Reviews 2008; 4 (2) . https://dx.doi.org/10.2174/157339408784310142
DOI https://dx.doi.org/10.2174/157339408784310142 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Applications of HPLC-MALDI-TOF MS/MS Phosphoproteomic Analysis in Oncological Clinical Diagnostics
Current Proteomics Protein Tyrosine Phosphatases, New Targets for Cancer Therapy
Current Cancer Drug Targets S100A1: Structure, Function, and Therapeutic Potential
Current Chemical Biology Application of Radiolabeled Antibodies in Targeting Therapy of Breast Cancer
Current Molecular Imaging (Discontinued) Radiolabeled Sugars Used for PET and SPECT Imaging
Current Radiopharmaceuticals Cytokines and their Antagonists as Therapeutic Agents
Current Medicinal Chemistry Meet Our Editorial Board Member:
Anti-Cancer Agents in Medicinal Chemistry Role of Apoptosis and Proinflammatory Cytokines in Influenza Virus Morbidity and Mortality
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Tumor Promoters - Microcystin-LR, Nodularin and TNF-α and Human Cancer Development
Anti-Cancer Agents in Medicinal Chemistry Patented Small Molecules Used for Reprogramming
Recent Patents on Regenerative Medicine Reprograming Carcinoma Associated Fibroblasts by microRNAs
Current Molecular Medicine Triterpenoids for Cancer Prevention and Treatment: Current Status and Future Prospects
Current Pharmaceutical Biotechnology Marine Metabolites Overcoming or Circumventing Multidrug Resistance Mediated by ATP-Dependent Transporters: A New Hope for Patient with Tumors Resistant to Conventional Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry 1,5-Dioxaspiro[2.4]heptanes
Current Chemical Biology Polycation-Based Gene Therapy: Current Knowledge and New Perspectives
Current Gene Therapy Spongistatins as Tubulin Targeting Agents
Current Pharmaceutical Design Melatonin in Bacterial and Viral Infections with Focus on Sepsis: A Review
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Endoglin-Targeted Cancer Therapy
Current Drug Delivery Stem Cells and Combinatorial Science
Combinatorial Chemistry & High Throughput Screening Protein Phosphatase 1 and Its Complexes in Carcinogenesis
Current Cancer Drug Targets